Introduction
Gene therapy involves the introduction of genetic material (including DNA, RNA, small interfering RNA or antisense oligonucleotides) into cells to correct cellular dysfunction or to provide new functions in order to cure or slow the progression of diseases. To date, over 1800 gene therapy clinical trials have been approved worldwide (Ref. 1) . T cell gene therapy represents an emerging therapeutic option for use against malignancies, infections and certain monogenic diseases. The ability to harvest, manipulate and reinfuse engineered T cells has made them attractive targets for gene therapy. Pioneering trials have already been undertaken to treat inherited T cell deficiency, redirect T cell antigen specificity, confer resistance to human immunodeficiency virus (HIV) and incorporate suicide genes to safeguard against graft-versus-host disease (GvHD) in the allogeneic transplant setting. As T cells are long lived cells, with periods of quiescence and active proliferation, integrating vector systems have generally been used to modify T cells, and here we review clinical experiences with γ-retroviral and lentiviral vectors (γRVs and LVs, respectively) and consider the potential of integrating transposon-based vectors, as well as transient expression of gene-modifying nuclease enzymes.
Long-term gene expression in T cells mediated by γRV
Murine γRV with intact long-term repeats (LTRs) flanking a transgene expression cassette, and packaged using stable cell lines, which provide accessory packaging and envelope components, have been widely exploited for T cell modification. Efficient γRV-mediated gene integration requires actively proliferating target cells, and T cell activation procedures have evolved from PHA stimulation, to activation with anti-CD3 antibody and currently beads conjugated with anti-CD3 and anti-CD28 antibodies.
γ-retroviral T cell gene therapies are summarised in Table 1 . Initial gene marking studies (Ref.
2) tracked tumour-infiltrating lymphocytes mediating regression of metastatic melanoma using a retroviral vector encoding a gene for resistance to neomycin. Soon afterward, autologous T cells from infants with adenosine deaminase (ADA) enzyme deficiency, a form of severe combined immunodeficiency (SCID), were reconstituted using γRV (Refs 3, 4). Both patients remained free from serious infections, on reduced doses of enzyme replacement (Ref. 5) . Although the clinical benefit was limited because of low gene transfer rates, retroviral gene transfer proved feasible, and gene-modified autologous cells persisted long-term without causing adverse effects.
Suicide gene therapies
Another early T cell immunotherapy trial recruited patients with HIV infection and modified CD8+ cytotoxic T cells by retroviral transduction with a herpes simplex virus thymidine kinase (HSV-TK) fusion gene. Although technically feasible, the main limitation was host-mediated immune responses against the transgene (Ref. 6 ). In 1997, Bonini et al. reported the use of allogeneic T cells engineered to express HSV-TK to render cells sensitive to the prodrug ganciclovir (GCV) and safeguard against GvHD (Ref. 7) , and similar studies were subsequently reported by a number of other groups (Refs 8, 9) . Donor T cells modified with the HSV-TK suicide gene were administered to patients with leukemic relapse and GvHD was effectively controlled by GCV-induced elimination of the transduced cells (Ref. 7) . Tiberghien et al. also demonstrated that the use of HSV-TK expressing donor T cells in 12 patients at the time of allogeneic Expert Reviews in Molecular Medicine, 1 of 10.
bone marrow transplantation was feasible and associated with persistent circulation of modified cells, GCV-sensitive GvHD, and the absence of acute toxicity (Ref. 9) . A similar clinical strategy using an almost identical vector with HSV-TK/NeoR led to secondary graft rejection in two of three treated patients due to immunogenicity of infused T cells (Ref. 10) .
In subsequent multicentre trials, leukemic patients were infused with donor lymphocytes expressing the HSV-TK suicide gene, following haploidentical stemcell transplantation. It was reported that 22 of 28 patients who received genetically modified T cells achieved rapid T cell immune recovery, with the development of a polyclonal repertoire protective against pathogens, leading to a significant long-term reduction of infection-related mortality. Of note, ten patients developed acute GvHD and one developed chronic GvHD, which were controlled by induction of the suicide gene (Ref. 11) . In a follow-up study of these 22 patients, new insights into the biologic events leading to the immune reconstitution after HSV-TK cell infusions were provided. It was suggested that the infused T cells that carried the suicide gene supported de novo generation of T cells from thymus-dependent pathways, leading to long-term immune reconstitution (Ref. 12) . In other studies, transduced T cells were detectable in nine leukemic patients for up to 5 years with seven of nine patients alive and in complete remission (Ref. 13) . A recent publication reports the production and first-in-man use of mismatched donor T cells modified with a γRV expressing a HSV-TK fused to a truncated CD34 marker protein for magnetic selection. Circulating gene-modified T cells were detectable by flow cytometry and by molecular tracking in all three subjects. There was resolution of viral infections, concordant with detected antigen-specific T cell responses, and gene-modified cells persisted for over a year (Ref. 14) .
As HSV-TK is virus-derived and immunogenic, alternative suicide genes have also been investigated. Di Stasi et al. devised an inducible T cell safety switch that is based on the human caspase 9. When exposed to a synthetic dimerising drug, the inducible caspase 9 to express a CAR directed against diasialoganglioside GD2, a non-viral tumour-associated antigen expressed by human neuroblastoma cells. They reasoned that these genetically engineered lymphocytes would receive optimal costimulation after engagement of their native receptors, enhancing survival and antitumour activity mediated through their chimeric receptors (Ref. 25 ). Four of the eight patients with evaluable tumours had evidence of tumour necrosis or regression including a complete and sustained remission. In a follow up study, the analysis of the long-term fate of these low-level persisting CAR cells was performed on a total of 19 subjects with high-risk neuroblastoma, including the original 11 patients. CAR cells persisted at low levels for as long as 4 years, with a highly statistically significant association between prolonged detection and the number of helper CD4 and central memory T cells. Of the 11 patients with active disease at the time of infusion, three patients achieved complete response (Ref. 26).
Second-generation CARs incorporating additional signalling domains derived from costimulatory molecules such as CD28 were assessed against B cell lymphomas expressing the CD19 antigen (Ref. 
Lentiviral-mediated T cell modification
In contrast to oncoretroviral preintegration complexes (PICs), lentiviral PIC has the capability of actively transporting into the nucleus through nuclear pore complexes in an adenosine triphosphate ( HIV therapies Lentiviral T cell gene therapies are summarised in Table 1 
αβ TCR gene therapies
In a recent trial carried out with an affinity-enhanced TCR specific for the HLA-A * 01-restricted MAGE-A3 tumour antigen, a melanoma and a myeloma patient were treated with autologous modified T cells. Both subjects encountered severe cardiac toxicity owing to off-target reactivity, developed cardiogenic shock and died within a few days of T-cell infusion (Refs 79, 80) . This was an unexpected and unpredictable consequence of cross recognition of unrelated cardiac antigen by the introduced TCR, underlining the difficulty in modelling such consequences ahead of clinical application.
Additional studies that are planned include treatment of patients with locally advanced or metastatic melanoma, with CD8+ T cells engineered to express the αβ chains of a high affinity TCR specific for the HLA-A * 0201-restricted MART-1 melanoma tumour antigen, together with the HSVl-sr39tk suicide gene, or with autologous PBLs expressing a αβ TCR specific for tyrosinase. For myeloma, MAGE-A3 and NY-ESO-1 TCRs post-ASCT and for the treatment of synovial sarcoma, NY-ESO-1 TCR transgenes will also be carried by LVs, as NY-ESO-1 and LAGE-1 TCRs for hepatocellular carcinomas.
For HIV therapy, gag-specific TCR (the University of Pennsylvania, Philadelphia) and RNAi For ovarian cancer, an alpha-folate CAR, following a clinical trial with γRV (Ref. 24) , and a mesothelin CAR are tested in clinical trials currently recruiting from the University of Pennsylvania, Philadelphia. In nonHodgkin lymphoma, CD19 CAR only, CD19 CAR together with a truncated EGFR in central memory T cells, or bi-specific CMV-TCR and CD19 CAR T cells will be infused to patients. For acute lymphoid leukaemia, CD19 CARs have also been designed in an autologous setting. Finally, patients with B-lymphoid malignancies will be infused with allogeneic CD8T cells expressing CD19 CARs (data collected from http://www.wiley.com/legacy/wileychi/ genmed/clinical/ and http://www.clinicaltrials.gov/). Interestingly, several companies including big pharmaceuticals have taken over to develop CAR T cells into clinical products (Ref. 83 ).
Non-viral transposon-based T cell engineering
Non-viral gene transfer technologies offer the prospect of more cost effective and less biologically complex alternatives to viral methodologies, with reduced concerns related to safety, host immune response and manufacturing costs. Plasmid-based gene transfer could facilitate investigation of a greater variety of transgene cassettes, and allow rapid evaluation of new receptors. This is an important consideration in the context of αβ TCRs, where multiple HLA-peptide specific receptors will need to be provided, and for CAR receptors, which continue to rapidly evolve with revised costimulatory and selection domains.
DNA transposons have the ability to insert transgenes into host chromosomes for long-term transgene expression and are derived from natural genetic elements residing in the genome as repetitive sequences that transfer through a direct cut-and-paste mechanism, called transposition. Sleeping Beauty, a reactivated Tc1/mariner-like element from fossils of the salmonid fish genome (Ref. In primary human T cells (Table 1) . SB delivery of CD19 CARs has led to early-phase human trials that are currently assessing safety and feasibility of administering these autologous genetically modified T cells into patients with high-risk B-lymphoid malignancies undergoing autologous HSCT. T cells with redirected specificity were efficiently generated with plasmids from the Sleeping Beauty system, and expansion was achieved for both CD4+ and CD8+ T cells expressing CAR with CD19+ artificial antigen-presenting cells (Refs 93, 94) .
Overall, eight clinical trials have opened recently using the Sleeping Beauty system for non-viral ex vivo genetic modification of either autologous T cells, HLA-matched allogeneic T lymphocytes or umbilical cord blood lymphocytes for the treatment of lymphoma, and autologous T cells for the treatment of CLL at the Anderson Cancer Center and the University of Texas (http://www.wiley.com/legacy/ wileychi/genmed/clinical/), with no acute toxicities reported to date.
Future developments
The rapid advancement of genome editing techniques holds much promise for the field of human gene therapy. Among the upcoming methods of lymphocyte genetic modification, the zinc finger nuclease (ZFN Clustered regularly interspaced short palindromic repeats (CRISPR) are clusters of brief DNA sequences that read similarly forward and backward, found in many types of bacteria. Since 2013, the CRISPR/Cas system has been used for gene editing (adding, disrupting or changing the sequence of specific genes) and gene regulation in various species. By delivering the Cas9 protein and appropriate guide RNAs into a cell, the genome can be cut at any desired location (Ref. 102) . Therefore, CRISPR could make gene therapies more broadly applicable, from simple genetic disorders to eventually more complex diseases involving multiple genes (Ref. 103) .
Overall, engineered T cells offer enormous therapeutic potential, with technologies evolving to allow modification of either autologous or allogeneic populations, which will need to be carefully assessed in welldesigned clinical studies. 
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